Omics-Based Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Phase, By Study Design, By Indication, By Region & Competition, 2020-2030F

Description

The global Omics-Based Clinical Trials Market was valued at USD 26.67 billion in 2024 and is projected to experience substantial growth during the forecast period, with a compound annual growth rate (CAGR) of 7.25% through 2030. Omics-based clinical trials integrate advanced omics technologies to collect detailed molecular data from patients participating in clinical studies. Omics encompasses a range of high-throughput techniques used in biology and medicine to analyze biological molecules at the molecular level. These techniques include genomics (the study of genes and DNA), proteomics (the study of proteins), metabolomics (the study of small molecules and metabolites), transcriptomics (the study of RNA and gene expression), and more. A key objective of omics-based clinical trials is to stratify patients into subgroups based on their molecular profiles, enabling more targeted and personalized healthcare interventions.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 26.67 Billion
Market Size 2030	USD 40.26 Billion
CAGR 2025-2030	7.25%
Fastest Growing Segment	Interventional Studies
Largest Market	North America

However, omics-based clinical trials face challenges such as data standardization, reproducibility issues, and the need for advanced bioinformatics capabilities. The accuracy and reliability of omics data are crucial for successful trials. For example, an article published in April 2024 highlights the growing significance of omics-based biomarkers in managing metabolic dysfunction-associated steatotic liver disease (MASLD), where these biomarkers aid in risk stratification and identifying patients with advanced fibrosis who are at higher risk of adverse outcomes. The increasing adoption of omics-based clinical trials is expected to further propel market growth.

Key Market Drivers:

Advancements in Omics Technologies

Recent developments in high-throughput sequencing have made these techniques faster, more precise, and cost-effective. Technologies like single-cell sequencing enable the examination of genetic material at an individual cell level, revealing cellular heterogeneity. Mass spectrometry tools have become more sensitive and precise, allowing the identification and quantification of proteins and metabolites in complex biological samples. Additionally, advancements in mass spectrometry imaging (MSI) enable the spatial mapping of molecules within tissues. Cryo-electron microscopy (cryo-EM) has revolutionized the structural analysis of proteins, achieving near-atomic resolution. X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy continue to enhance molecular structure resolution. Technologies such as stable isotope labeling and flux analysis offer insights into metabolic pathways, while quantitative proteomics methods, including isobaric labeling and label-free approaches, allow precise protein quantification.

A report from the Mayo Clinic in February 2023 highlights a new approach in genomics research, shifting some omics studies from traditional settings like hospitals to individuals' homes, particularly in rural and underserved areas. This change is expected to improve access to clinical trials, expanding participant pools and enabling more diverse data collection.

Key Market Challenges:

Sample Size and Diversity

One of the challenges of omics-based clinical trials is obtaining an adequate number of patient samples, particularly for rare diseases or genetically specific subpopulations. The availability of diverse patient samples is crucial, as these trials often require large and varied cohorts to generate reliable results. Biological variability among patients within the same disease category can be substantial, making it necessary to include larger sample sizes for statistical validity. Furthermore, ensuring genetic and ethnic diversity in clinical trial populations is essential for the broader applicability of findings. Omics-based trials often involve subgroup analysis based on genetic or molecular characteristics, and recruiting patients that meet these specific criteria can be time-consuming and resource-intensive. Delays in recruitment and data collection can hinder the trial process. Additionally, obtaining informed consent for genetic and molecular profiling, as well as addressing privacy concerns, can also present challenges.

The integration and interpretation of large, complex omics data sets also require advanced bioinformatics tools, which can further complicate the analysis, especially when dealing with large and diverse sample sizes.

Key Market Trends:

Integration of Multi-Omics Data

Different omics technologies provide unique perspectives on the molecular mechanisms underlying diseases. Integrating data from multiple omics disciplines offers a more comprehensive view of disease processes by examining the interplay of genes, proteins, metabolites, and other factors. This integration enhances the identification and validation of biomarkers for disease diagnosis, prognosis, and treatment response. Combining genetic, proteomic, and metabolic profiles leads to more accurate and robust biomarker discovery.

The integration of multi-omics data is pivotal for patient stratification, allowing researchers to classify patients based on molecular profiles and design more targeted clinical trials. This approach also facilitates the development of personalized therapies tailored to individual genetic, proteomic, and metabolic characteristics, leading to more effective treatments. In drug development, multi-omics integration helps to understand how drugs interact with various molecular components, providing insights into potential adverse effects and guiding drug design. For complex diseases like cancer, multi-omics data integration aids in understanding intricate molecular interactions, facilitating the identification of novel therapeutic targets and strategies. This integration aligns with a systems biology approach, offering a holistic understanding of biological systems as interconnected networks of genes, proteins, and metabolites.

Key Market Players:

Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer Inc.
Covance Inc.
Novo Nordisk
Rebus Bio

Report Scope:

This report segments the global omics-based clinical trials market into various categories and provides a comprehensive analysis of market trends:

By Phase:

Phase I
Phase II
Phase III
Phase IV

By Study Design:

Expanded Access Studies
Interventional Studies
Observational Studies

By Indication:

Cardiology
CNS Diseases
Genetic Diseases
Immunology
Oncology
Respiratory Diseases
Skin Diseases

By Region:

North America: United States, Canada, Mexico
Asia-Pacific: China, India, South Korea, Australia, Japan
Europe: Germany, France, United Kingdom, Spain, Italy
South America: Brazil, Argentina, Colombia
Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape:

This section provides detailed analysis and profiles of the major players in the global omics-based clinical trials market.

Available Customizations:

TechSci Research offers tailored customization options for this market report. These include a detailed analysis of additional market players (up to five) as per specific company needs.

Product Code: 18961

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omics-Based Clinical Trials Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV.)
- 5.2.2. By Study Design (Expanded Access Studies, Interventional Studies, and Observational Studies)
- 5.2.3. By Indication (Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. Asia Pacific Omics-Based Clinical Trials Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Phase
- 6.2.2. By Study Design
- 6.2.3. By Indication
- 6.2.4. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Omics-Based Clinical Trials Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Phase
    - 6.3.1.2.2. By Study Design
    - 6.3.1.2.3. By Indication
- 6.3.2. India Omics-Based Clinical Trials Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Phase
    - 6.3.2.2.2. By Study Design
    - 6.3.2.2.3. By Indication
- 6.3.3. Australia Omics-Based Clinical Trials Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Phase
    - 6.3.3.2.2. By Study Design
    - 6.3.3.2.3. By Indication
- 6.3.4. Japan Omics-Based Clinical Trials Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Phase
    - 6.3.4.2.2. By Study Design
    - 6.3.4.2.3. By Indication
- 6.3.5. South Korea Omics-Based Clinical Trials Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Phase
    - 6.3.5.2.2. By Study Design
    - 6.3.5.2.3. By Indication

7. Europe Omics-Based Clinical Trials Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Phase
- 7.2.2. By Study Design
- 7.2.3. By Indication
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Omics-Based Clinical Trials Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Phase
    - 7.3.1.2.2. By Study Design
    - 7.3.1.2.3. By Indication
- 7.3.2. Germany Omics-Based Clinical Trials Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Phase
    - 7.3.2.2.2. By Study Design
    - 7.3.2.2.3. By Indication
- 7.3.3. Spain Omics-Based Clinical Trials Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Phase
    - 7.3.3.2.2. By Study Design
    - 7.3.3.2.3. By Indication
- 7.3.4. Italy Omics-Based Clinical Trials Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Phase
    - 7.3.4.2.2. By Study Design
    - 7.3.4.2.3. By Indication
- 7.3.5. United Kingdom Omics-Based Clinical Trials Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Phase
    - 7.3.5.2.2. By Study Design
    - 7.3.5.2.3. By Indication

8. North America Omics-Based Clinical Trials Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Phase
- 8.2.2. By Study Design
- 8.2.3. By Indication
- 8.2.4. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Omics-Based Clinical Trials Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Phase
    - 8.3.1.2.2. By Study Design
    - 8.3.1.2.3. By Indication
- 8.3.2. Mexico Omics-Based Clinical Trials Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Phase
    - 8.3.2.2.2. By Study Design
    - 8.3.2.2.3. By Indication
- 8.3.3. Canada Omics-Based Clinical Trials Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Phase
    - 8.3.3.2.2. By Study Design
    - 8.3.3.2.3. By Indication

9. South America Omics-Based Clinical Trials Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Phase
- 9.2.2. By Study Design
- 9.2.3. By Indication
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Omics-Based Clinical Trials Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Phase
    - 9.3.1.2.2. By Study Design
    - 9.3.1.2.3. By Indication
- 9.3.2. Argentina Omics-Based Clinical Trials Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Phase
    - 9.3.2.2.2. By Study Design
    - 9.3.2.2.3. By Indication
- 9.3.3. Colombia Omics-Based Clinical Trials Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Phase
    - 9.3.3.2.2. By Study Design
    - 9.3.3.2.3. By Indication

10. Middle East and Africa Omics-Based Clinical Trials Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Phase
- 10.2.2. By Study Design
- 10.2.3. By Indication
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Omics-Based Clinical Trials Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Phase
    - 10.3.1.2.2. By Study Design
    - 10.3.1.2.3. By Indication
- 10.3.2. Saudi Arabia Omics-Based Clinical Trials Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Phase
    - 10.3.2.2.2. By Study Design
    - 10.3.2.2.3. By Indication
- 10.3.3. UAE Omics-Based Clinical Trials Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Phase
    - 10.3.3.2.2. By Study Design
    - 10.3.3.2.3. By Indication

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Omics-Based Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1. Parexel International Corporation
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
16.2. Pharmaceutical Product Development (PPD)
- 16.2.1. Business Overview
- 16.2.2. Company Snapshot
- 16.2.3. Products & Services
- 16.2.4. Financials (In case of listed companies)
- 16.2.5. Recent Developments
- 16.2.6. SWOT Analysis
16.3. Charles River Laboratory
- 16.3.1. Business Overview
- 16.3.2. Company Snapshot
- 16.3.3. Products & Services
- 16.3.4. Financials (In case of listed companies)
- 16.3.5. Recent Developments
- 16.3.6. SWOT Analysis
16.4. ICON plc
- 16.4.1. Business Overview
- 16.4.2. Company Snapshot
- 16.4.3. Products & Services
- 16.4.4. Financials (In case of listed companies)
- 16.4.5. Recent Developments
- 16.4.6. SWOT Analysis
16.5. SGS SA
- 16.5.1. Business Overview
- 16.5.2. Company Snapshot
- 16.5.3. Products & Services
- 16.5.4. Financials (In case of listed companies)
- 16.5.5. Recent Developments
- 16.5.6. SWOT Analysis
16.6. Eli Lilly and Company
- 16.6.1. Business Overview
- 16.6.2. Company Snapshot
- 16.6.3. Products & Services
- 16.6.4. Financials (In case of listed companies)
- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
16.7. Pfizer Inc.
- 16.7.1. Business Overview
- 16.7.2. Company Snapshot
- 16.7.3. Products & Services
- 16.7.4. Financials (In case of listed companies)
- 16.7.5. Recent Developments
- 16.7.6. SWOT Analysis
16.8. Covance Inc.
- 16.8.1. Business Overview
- 16.8.2. Company Snapshot
- 16.8.3. Products & Services
- 16.8.4. Financials (In case of listed companies)
- 16.8.5. Recent Developments
- 16.8.6. SWOT Analysis
16.9. Novo Nordisk
- 16.9.1. Business Overview
- 16.9.2. Company Snapshot
- 16.9.3. Products & Services
- 16.9.4. Financials (In case of listed companies)
- 16.9.5. Recent Developments
- 16.9.6. SWOT Analysis
16.10.Rebus Bio
- 16.10.1. Business Overview
- 16.10.2. Company Snapshot
- 16.10.3. Products & Services
- 16.10.4. Financials (In case of listed companies)
- 16.10.5. Recent Developments
- 16.10.6. SWOT Analysis